Piramal Pharma Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company’s Board of Directors approved the financial statements, which show key performance indicators for the period. The results highlight revenue from operations and profitability, alongside other comprehensive income and earnings per share data.
Piramal Pharma Limited Reports Q1 FY2027 Financials
Piramal Pharma Limited officially disclosed its unaudited standalone and consolidated financial results for the first quarter of the fiscal year 2027, ending on June 30, 2026. The company’s Board of Directors convened on July 29, 2026, to review and approve these critical financial statements.
Standalone Financial Highlights
For the quarter ended June 30, 2026, Piramal Pharma Limited reported total income of ₹1,239.58 Crores. The profit before tax stood at ₹149.48 Crores, and after accounting for tax expenses, the net profit after tax was ₹113.48 Crores. These figures represent a limited review by the statutory auditors.
Consolidated Financial Overview
On a consolidated basis, the company’s total income for the same period reached ₹2,359.33 Crores. The profit before tax for the quarter was ₹(7.46) Crores, and the net loss after tax amounted to ₹(69.39) Crores. The consolidated results also include details on other comprehensive income/loss and earnings per share.
Key Financial Metrics
The standalone earnings per equity share (EPS) for the period were ₹0.85 (Basic and Diluted). On a consolidated basis, the basic and diluted EPS were both ₹(0.52). The company also detailed its other comprehensive income/(loss) for both standalone and consolidated statements, reflecting changes in post-employment benefit plans and cash flow hedges.
Information Availability
The full financial results, along with the limited review reports from the statutory auditors, are available on the company’s website at www.piramalpharma.com. This disclosure aligns with the requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Board meeting commenced at 5:30 pm and concluded at 8:30 pm on July 29, 2026.
Source: BSE
